Company
Message
To be the best partner in the development and manufacturing of middle-molecular drugs, building trust, accumulating thoughts, and working together to achieve goals
Middle-molecular drugs are attracting wide attention from the pharmaceutical industry as a new drug discovery modality that combines the advantages of conventional low-molecular and high-molecular drugs.
In recent years, there has been a rapid increase in the need for such products because they can be produced by chemical synthesis, targeting diseases that have previously been considered impossible to treat.
Against the backdrop of these increasingly sophisticated drug discovery research, Syncrest Inc. was established in 2023 as a joint venture between Otsuka Chemical Co., Ltd. and Yokogawa Electric Corporation.
Our strength lies in our "in-line measurement integrated flow continuous synthesis method," which combines the flow synthesis method based on halogenation technique and catalyst technology cultivated by Otsuka Chemical through the manufacture of small molecule pharmaceuticals with Yokogawa's in-line sensing technology, which is the world's top level measurement technology.
Our mission is to provide innovative solutions and value to the pharmaceutical industry by leveraging our unique know-how, which is unprecedented in the world, and responding to issues in drug discovery research.
Currently, our R&D division is based at Shonan Health Innovation Park in Fujisawa City, Kanagawa Prefecture, and in cooperation with the multipurpose plant in Naruto City, Tokushima Prefecture, where our manufacturing and quality control division is located, we have established an integrated system that covers everything from R&D support to the manufacture of middle-molecular raw materials, intermediates, and APIs.
Our mission is to contribute to the development of pharmaceuticals and human health by supplying and supporting the development of middle-molecular drug substances and related compounds. We will further accelerate our contract R&D-based manufacturing business (CRDMO business) for high-quality, short-delivery, and low-cost middle-molecular drugs that our customers demand.
In addition, our motto is "the spirit of co-creation," which goes beyond simply providing services and solutions to contribute to the health of people together. Our goal is to create innovation while fostering trust with our customers and achieve sustainable growth in the ever-advancing drug discovery industry.
In the future, the range of applications for middle-molecular drug discovery is expected to expand even further, and beyond that, the possibilities are expected to expand without limit.
With a view to the multifaceted use of our core technology, "In-line Measurement Integrated Flow Continuous Synthesis Method", we have started development not only in drug discovery but also in a wide range of fields such as supplements, beauty, and cosmetics, and will continue to promote further research and development in order to deliver our proud "Made in Japan" quality and technology to all over the world.
RepresentativeXU PENGYU